EMA Authorised: Afqlir (aflibercept) — Sandoz GmbH

View source ↗

Summary

The EMA authorised Afqlir (aflibercept) from Sandoz GmbH for retinal conditions including wet age-related macular degeneration, macular edema, diabetic macular …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Macular Edema
• Retinal Vein Occlusion
• Wet Age-related Macular Degeneration

Drugs mentioned

• Afqlir (aflibercept)

Snippet

Status: Authorised. Therapeutic area: Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion. MAH: Sandoz GmbH. Decision date: 03/03/2026